Ranexa Articles
US cardiologists attitudes to vernakalant and ranolazine Rxing
6 February 2012
Gilead files patent infringement suit against Lupin over Ranexa; Mylan’s generic nabumetone cleared by FDA
16 July 2010
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
CV's Ranexa cleared in the UK and Germany
9 March 2009
CV Thera narrows loss on Ranexa sales
9 March 2009
CV board rejects Astellas bid for second time
2 March 2009
Japanese stock prices week to Feb 2, 2009
9 February 2009
CV's 3rd-qtr 2008 loss narrows 26% to $25.4M
17 November 2008
Expanded US label for CV's angina drug
17 November 2008
CV's ranolazine shortens QT interval
1 September 2008
EMEA grants Ranexa brand name
1 September 2008
CV's ranolazine shortens QT interval in LQT3
7 April 2008
FDA assesses Ranexa
17 December 2007
Ranexa added to new ACC/AHA guidelines
20 August 2007
CV Thera cuts 2nd-qtr loss 22% on Ranexa
13 August 2007
CV Thera identifies diabetes potential for Ranexa
16 July 2007
CV to save $75M via job and R&D cuts
4 June 2007
CV Thera narrows 1st-qtr 2007 loss to $55.1M
7 May 2007
CV Thera's Ranexa fails in ACS study
19 March 2007
CV Thera launches Ranexa in USA
3 April 2006
CV's fourth-quarter 2005 loss deepens 38%
13 March 2006
FDA approves Ranexa as angina drug
13 February 2006
CV Therapeutics' Ranexa get FDA OK
6 February 2006
CV Therapeutics amends its NDA on Ranexa
8 August 2005
Losses escalate at CV Therapeutics
9 August 2004
CV Thera initiates Ranexa study
9 August 2004
CV Therapeutics' Ranexa filed in EU
5 April 2004
FDA panel wants more safety data on CV Therapeutics Ranexa
15 December 2003
Ranexa to be reviewed by FDA committee
10 November 2003
Delay in review of CV Therapeutics' Ranexa
11 August 2003
CV Therapeutics files Ranexa for angina
6 January 2003
CV Therapeutics shares slump on analyst note
3 June 2002
CV Thera looking to raise $131 million
6 December 2001
CVT's ranolazine set for US filing in 2002
16 November 2001
CV Therapeutics third-quarter loss widens
22 October 2001
CV Therapeutics' second drug enters Phase III
3 July 2001
CV Therapeutics raises $120 million
9 August 2000
CVT enters pivotal studies with CVT-510
18 May 2000
CV Therapeutics soars on ranolazine data
23 August 1999
Phase II ranolazine data published
1 July 1999
Ranolazine to be marketed by Innovex
13 May 1999
CV Therapeutics - An Overlooked Opportunity
17 December 1998
CV Therapeutics Announces Public Offering
23 January 1998
Showing 1-53 of 53 articles
- 1
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
